U-Neuron Biomedical (ROCO:6973) Debt-to-Revenue : 0.32 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is U-Neuron Biomedical Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

U-Neuron Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$4.77 Mil. U-Neuron Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$4.90 Mil. U-Neuron Biomedical's annualized Revenue for the quarter that ended in Dec. 2023 was NT$30.05 Mil. U-Neuron Biomedical's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.32.

U-Neuron Biomedical Debt-to-Revenue Historical Data

The historical data trend for U-Neuron Biomedical's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U-Neuron Biomedical Debt-to-Revenue Chart

U-Neuron Biomedical Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

0.16

0.36

U-Neuron Biomedical Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	N/A	-	0.19	0.09	0.32

Competitive Comparison of U-Neuron Biomedical's Debt-to-Revenue

For the Biotechnology subindustry, U-Neuron Biomedical's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

U-Neuron Biomedical's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where U-Neuron Biomedical's Debt-to-Revenue falls into.

U-Neuron Biomedical Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

U-Neuron Biomedical's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(4.767	+	4.896)	/	27.023
	=	0.36

U-Neuron Biomedical's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(4.767	+	4.896)	/	30.046
	=	0.32

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

U-Neuron Biomedical Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of U-Neuron Biomedical's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

U-Neuron Biomedical (ROCO:6973) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » U-Neuron Biomedical Inc (ROCO:6973) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

https://en.u-neuron.com

U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.

U-Neuron Biomedical (ROCO:6973) Headlines

No Headlines